Assessing the safety features of electronic patient medication record systems used in community pharmacies in England

Oluwagbemileke Ojeleye, Anthony J. Avery & Matthew J. Boyd

Division of Social Research in Medicines and Health, School of Pharmacy, University of Nottingham, Nottingham, UK and Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK

Correspondence
Dr Matthew Boyd BPharm (Hons) PhD MRPharmS, School of Pharmacy, University of Nottingham, East Drive, University Park, Nottingham NG7 2RD, UK.
Tel.: +44 115 951 5061
Fax: +44 115 846 6249
E-mail: matthew.boyd@nottingham.ac.uk

Keywords
decision support, electronic patient medication record system, pharmacy computer system, safety alert, safety feature, safety warning

Received 10 December 2013
Accepted 5 February 2014
Accepted Article Published Online 17 February 2014

AIMS
To evaluate the ability of electronic patient medication record (ePMR) systems used in community pharmacies in England to detect and alert users about clinical hazards, errors and other safety problems.

METHODS
Between September 2012 and November 2012, direct on-site observational data about the performance of ePMR systems were collected from nine sites. Twenty-eight scenarios were developed by consensus agreement between a general practitioner and two community pharmacists. Each scenario was entered into the ePMR system, and the results obtained from the assessment of six unique systems in nine sites, in terms of the presence or absence of an alert, were recorded onto a prespecified form.

RESULTS
None of the systems produced the correct responses for all of the 28 scenarios tested. Only two systems provided an alert to penicillin sensitivity. No dose or frequency check was observed when processing a prescription for methotrexate. One system did not warn about nonsuitability of aspirin prescribed to a child of 14 years of age. In another system, it was not possible to record a patient’s pregnancy status. None of the six systems provided any warning for diclofenac overdose, high initiation dose of morphine sulfate or significant dose increase. Only one of the systems did not produce any spurious alerts.

CONCLUSIONS
The performance of the ePMR systems tested was variable and suboptimal. The findings suggest the need for minimum specifications and standards for ePMR systems to ensure consistency of performance.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
- Electronic patient medication record (ePMR) systems provide alerts about potential drug interactions between previously dispensed and newly prescribed medication.
- It has been suggested that there are problems, such as false alerts and overalerting.

WHAT THIS STUDY ADDS
- This study evaluated the ability of ePMR systems used in community pharmacies in England to alert users about medication-related hazards and errors.
- Alerts are not adequately implemented in most ePMR systems.
- Current systems are unreliable in highlighting clinically significant prescribing hazards other than drug–drug interactions and co-prescriptions.
- Pharmacists should not be over-reliant on ePMR systems in their current state of maturity.

Br J Clin Pharmacol / 78:2 / 401–409 / 401© 2014 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Pharmacists take numerous steps to ensure the safety of medications and patients in their care. These steps include checking prescriptions and dispensing labels for accuracy, ensuring suitability of medications, doses and directions, and assessing prescriptions for potential problems, such as interactions with other medications and drug allergies. These facilitate reduction in medication errors and dispensing of potentially hazardous drugs and unsafe co-prescriptions [1, 2].

In a recent retrospective case record review study of 1000 adults who died in 2009 in 10 acute hospitals in England, a wide range of problems were identified in patients whose death was judged as preventable. Unacceptable fluid levels and medication problems, such as side-effects, inappropriate use, failure to give prophylactic care and anaphylaxis accounted for 21.1% of the most frequent problems [3]. Wrong dose, frequency, route or quantity, mismatching between patient and medicine, allergy, contraindication and adverse drug reaction have also been identified as errors arising from medication use [4]. Recent work that investigated medication error in general practices in England showed that one in eight patients is subject to a medication error [5]. To achieve improvements in medication and patient safety, the World Health Organization reiterates the requirement for a wide range of actions such as performance improvement, risk management, and provision of a safe healthcare environment, encompassing appropriate use of medicines, equipment safety and safe clinical practice [6].

In the UK, at the time of writing this article, the majority of prescriptions presented to community pharmacies are paper based and these require re-entry of the order into the electronic patient medication record (ePMR) system. A new service, the Electronic Prescription Service (EPS), has been introduced and is being deployed through two key releases. The service allows for electronic transmission of prescriptions from the general practice (GP) surgery to the pharmacy, which means that in those cases, it is possible for the ePMR system to be populated with information automatically from GP systems, but this is still in the roll-out phase and not in widespread use. Pharmacists use their knowledge, with the support of ePMR systems embedded with safety features, to complete their assessment of prescribed medication. Clinical and professional reasons have both been cited as some of the reasons for installing ePMR systems by pharmacy companies [7]. Previous studies have shown ePMR systems to be useful in alerting pharmacists to potential drug interactions between previously dispensed and newly prescribed medication [8].

In many countries around the world, the sensitivity and specificity of safety warnings, the way in which they are presented, what a user gets warned about, and the category and severity level of alerts are some of the areas where variations and problems exist in ePMR systems [9–14]. Other problems include missing alerts, inadequate alert information and false alerts. Overalerting as a result of delays in implementation of prescribing guidance updates, beneficial therapeutic duplication of medications, such as antihypertensives, and use of multiple drug strengths to personalize drug regimens could lead to ‘alert fatigue’ and automatic behaviour towards alerts without consideration of the implications [9, 12, 15, 16]. Technologies such as ePMR systems have also been known to introduce new errors, such as separation of functions that facilitate double dosing and incompatible orders and fragmented displays that prevent a coherent view of patients’ medications [17].

A proactive approach to safety is required in the identification and prevention of potential medication errors and harm to patients [18]. Even though the performance of safety features and alerts in hospital and community pharmacy ePMR systems in some countries is well documented [9, 11–14, 19, 20], such data about community pharmacy ePMR systems in England do not exist. Over one billion prescription items were dispensed in the community in England in 2012 [21]. This number has been steadily increasing over recent years, with greater potential for medication errors as the number of medicines dispensed increases. This increased number of medicines also presents huge opportunities and challenges for pharmacists, to stop errors and harm to patients. In addition, the dispensing stage of the medication use process is usually the last opportunity to stop an error from passing through to the patient in primary care and should remain invulnerable [22].

This study aimed to evaluate the ability of ePMR systems, used in community pharmacies in England, to detect and alert users to a sample of clinically hazardous interactions, errors and problems during pharmacy order entry. Currently, there is no minimum specification for the clinical functionality of ePMR systems used in community pharmacies in England. In this study, we examined systems that have been approved by the National Health Service in England. All these systems have to be capable of using EPS Release 2 (R2) [23].

Methods

This study was part of a larger observational study in eight community pharmacies, exploring the use of ePMR systems and alerts in the practice setting. Firstly, we approached community pharmacies in the Nottinghamshire area, UK. The pharmacies were invited, with permission from their superintendent pharmacists, by post or telephone, to participate in the observational study. The assessment took place in the eight community pharmacies that agreed to participate in the observational study. All but one of the ePMR systems were tested in these com-
community pharmacies. We identified an extra ePMR system, and this system was supplied by the vendor and tested in a demonstration setting. This sample represented all six ePMR systems available in community pharmacies in England in August 2012. Direct, on-site observational data were collected between September 2012 and November 2012. The names of the ePMR systems have been anonymized as S1–S6 to preserve ePMR system and vendor anonymity.

Test scenarios
Prespecified scenarios against which the ePMR systems were to be evaluated were developed to test prompting of clinically important events or the spurious alerting of nonclinically important events. Scenarios were devised by consensus agreement between a general practitioner and two community pharmacists following a review of primary literature; guidance from the British National Formulary 63 [24] and Summary of Product Characteristics. These scenarios included appropriate alerts when contraindicated drugs or hazardous drug–drug combinations were entered into the ePMR systems. The response of the ePMR system was recorded as ‘yes’ where an alert was generated or ‘no’ if the ePMR system did not produce an alert.

Twenty-eight scenarios were used to check for drug–drug interactions, other hazardous situations where evidence exists that an ePMR system should alert the user about potential errors and harm during order entry, and spurious alerts. These scenarios included various patient demographics and conditions such as hypertension, asthma and rheumatoid arthritis. Some of the scenarios were adapted from previous studies described elsewhere [12, 25]. Tables 1–3 show the clinical rationale for each of the scenarios tested. The scenarios in Tables 1 and 2 are potentially hazardous based on the clinical rationale outlined above and should trigger an alert in the ePMR system. The scenarios in Table 3 should not trigger an alert. These include scenarios where other drugs in the class have clinically significant interactions but the test drug does not, or as a result of concomitant use being downgraded due to new evidence.

Rationale for the test scenarios
The rationale for the tests is described in Tables 1–3. The first set of tests, described in Table 1, was designed to test the performance of ePMR systems with respect to checking drug–drug interactions and hazardous co-prescriptions. The second set, described in Table 2, was designed to test information that could have been provided either from the prescription or from the patient medication record without recourse directly to the general practitioner. The third set, described in Table 3, looked at the potential for overalerting. Allergies and pregnancy data are not routinely communicated directly on prescriptions. Nevertheless, pharmacists may be aware of this information directly from the patient and would expect to receive appropriate alerts if the information was recorded in the ePMR system.

Test process
One researcher (OO) visited each participating pharmacy at a mutually convenient time to collect relevant data about the performance of their pharmacy’s ePMR system. Dummy patient data and the scenarios were entered into the ePMR system. All scenarios were tested on each of the

| Test | Dispensing scenario (alert expected = Yes) | Rationale |
|------|------------------------------------------|-----------|
| A1   | Sildenafil prescribed to a patient who is also receiving a nitrates | Sildenafil significantly enhances hypotensive effect of nitrates; avoid concomitant use |
| A2   | Ciprofloxacin prescribed to a patient who is taking cilostazol | Increased risk of nephrotoxicity when quinolones are given with cilostazol |
| A3   | Clarithromycin prescribed to a patient who is taking digoxin | Macrolides increase plasma concentration of digoxin; increased risk of toxicity |
| A4   | Erythromycin prescribed to a patient who is taking simvastatin, with no evidence that the patient has been advised to stop the simvastatin whilst taking the antibiotic | Increased risk of myopathy when simvastatin is given with erythromycin |
| A5   | Ibuprofen prescribed to a patient who is taking lithium carbonate | Excretion of lithium is reduced by nonsteroidal anti-inflammatory drugs; increased risk of toxicity |
| A6   | Verapamil prescribed to a patient who is taking atenolol | Taking verapamil with β-blocker may lead to severe hypotension and heart failure |
| A7   | Naproxen prescribed to a patient who is taking warfarin | Anticoagulant effect of coumarins is possibly enhanced by nonsteroidal anti-inflammatory drugs |
| A8   | Tagamet prescribed to a patient who is taking warfarin | Metabolism of coumarins is inhibited by cinmethine, the active ingredient in Tagamet, leading to enhanced anticoagulant effect |
| A9   | Fluvastatin prescribed to a patient who is taking warfarin | Fluvastatin enhances the anticoagulant effect of coumarins |
| A10  | Micogynon prescribed to a patient who is on carbamazepine | Carbamazepine accelerates the metabolism of estrogens; reduced contraceptive effect |
| A11  | St John’s Wort prescribed to a patient who is taking fluoxetine | Increased serotonergic effects when fluoxetine is given with St John’s Wort; avoid concomitant use |
| A12  | Tramacel prescribed to a patient who is taking paracetamol | Tramacel contains tramadol and paracetamol. Duplication of paracetamol and increased risk of paracetamol toxicity |
systems once. In the scenarios we used, the dosage instructions were created using the ePMR system’s dose codes and so we would expect the ePMR system to be capable of recognizing an error. Data were recorded on predesigned data-extraction sheets. Where a scenario required a historical medication record for an assessment, entry of any ‘newly prescribed’ medication was done at least 1 day after the initial entry of the ‘historical’ medication. Correct response was recorded if an alert was presented on screen when an alert was expected, or an alert required a historical medication record for an assessment, entry of any ‘newly prescribed’ medication was done at least 1 day after the initial entry of the ‘historical’ medication. Correct response was recorded if an alert was presented on screen when an alert was expected, or an alert

### Table 2

Clinical scenarios in relation to drug-allergies, contraindications, inappropriate doses, drug-route suitability, high-dose initiation of medicines and significant dose increase

| Test | Dispensing scenario tested (alert expected = Yes) | Rationale |
|------|---------------------------------------------------|-----------|
| **B. Drug allergy** | | |
| B1 | Fluvarix vaccine prescribed to a patient with egg allergy | Summary of Product Characteristics: contraindicated. British National Formulary: individuals with a history of egg allergy can be immunized with either an egg-free influenza vaccine, if available, or an influenza vaccine with an ovalbumin content <120 ng ml⁻¹ (facilities should be available to treat anaphylaxis). The ovalbumin content of Fluvarix is <100 ng ml⁻¹ |
| B2 | Phenoxymethylpenicillin prescribed to a patient with penicillin allergy | Contraindicated |
| **C. Contraindications (including age, gender and condition)** | | |
| C1 | Aspirin 300 mg tablet to be taken every 6 h when required (112 tablets), prescribed to an elderly patient of 70 years | Contraindicated; may be more sensitive to side-effects, especially drowsiness |
| C2 | Acivastine 8 mg capsule to be taken three times daily (84 capsules) prescribed to a female patient | Finasteride is not indicated for use in women or children |
| C3 | Finasteride prescribed to a female patient | Finasteride is not indicated for use in women or children |
| C4 | Methotrexate prescribed in pregnancy | Contraindicated |
| C5 | Propranolol 10 mg tablet to be taken four times daily (112 tablets) prescribed to a patient with asthma who is on salbutamol | β-Blockers, including those considered to be cardioselective (e.g. propranolol), should usually be avoided in patients with a history of asthma or bronchospasm |
| **D. Dose check** | | |
| D1 | Diclofenac sodium 50 mg tablet to be taken four times daily (112 tablets) | The daily dose of 200 mg is more than the maximum daily dose of 75–150 mg in two to three divided doses recommended by the British National Formulary for oral intake |
| D2 | Methotrexate 2.5 mg tablets, 15 mg to be taken daily (42 tablets) | Methotrexate dose is once weekly |
| **E. Drug-route check** | | |
| E1 | Timolol eye drops prescribed to a patient with asthma who is on salbutamol | British National Formulary states that β-blockers, even those with apparent cardioselectivity, should not be used in patients with asthma or a history of obstructive airways disease, unless no alternative treatment is available. In such cases, the risk of inducing bronchospasm should be appreciated and appropriate precautions taken |
| **F. High-dose initiation of medicines and significant dose increase** | | |
| F1 | MST Continus 100 mg tablets prescribed to a patient who had 10 mg recorded in the electronic patient medication record system | Significant dose increase |
| F2 | Morphine sulfate solution 20 mg ml⁻¹, 5 ml to be taken every 4–6 h when required | High-dose initiation |

### Table 3

Clinical scenarios where an alert would not be expected

| Test | Dispensing scenario (alert expected = NO) | Rationale |
|------|----------------------------------------|-----------|
| G1 | Pravastatin prescribed to a patient who is already taking warfarin | Unlike some statins, pravastatin is not known to affect the effect of anticoagulants. This scenario checks whether interactions are picked up at drug class, product level or both |
| G2 | Amoxicillin prescribed to a patient who is on Microgynon | Current recommendations issued by the Faculty of Sexual and Reproductive Health Care Clinical Effectiveness Unit in January 2011 are that no additional contraceptive precautions are required when combined oral contraceptives are used with non-enzyme-inducing antibiotics, unless diarrhoea or vomiting occurs [26] |
| G3 | Atenolol prescribed to a patient who is already taking amiodipine | Calcium-channel blocker and β-blocker combination may be used to treat high blood pressure or to relieve angina pain when either drug alone proves inadequate |
| G4* | Atenolol 75 mg, once daily (28 day treatment) | Requires dispensing of 25 mg and 50 mg tablets because the 75 mg product is not commercially available. Maximum daily dose can be up to 200 mg depending on the condition being treated |

*Drug-doubling.*
was not displayed on screen when it was not expected. The study was reviewed by the University of Nottingham, Medical School Research Ethics Committee and was given a favourable opinion. National Health Service research and development permission was obtained from Nottinghamshire Healthcare NHS Trust.

Results

Five unique ePMR systems licenced for EPS R2 in England were tested in the eight participating pharmacies, with a sixth ePMR system assessed in a demonstration setting. All the six ePMR systems assessed had safety features in them, alerting users about potential hazardous situations. Four of the eight participating pharmacies were using the same ePMR system (System S2) at the time of the assessment; the system responses observed in all four sites were the same. No system produced the anticipated responses for all of the 28 scenarios tested. Alerts were displayed in a pop-up window (two systems), in a fixed area for messages (one system), on a separate screen (one system) or as a dual warning in both a pop-up window and in a fixed message area (two systems).

The systems correctly identified the majority of hazardous co-prescriptions and drug–drug interactions (Table 4). Two of the ePMR systems identified all the 12 interactions that were assessed in this category. Systems S1 and S2 failed to highlight the potential for digoxin toxicity when co-prescribed with clarithromycin. Systems S2 and S3 failed to notify the user about potential hazards from coincident prescribing of paracetamol, when generic paracetamol and Tramacet (a product containing tramadol and paracetamol) were prescribed for the same patient on subsequent days. System S6 did not highlight the clinically significant interaction between fluoxetine and St John’s Wort. Further investigation of the settings for S6 highlighted that St John’s Wort drug name was not mapped to a physical product.

Table 5 shows the ability of the ePMR systems to highlight drug-allergy issues, contraindications, inappropriate doses, drug-route suitability, issues with high-dose initiation of medicines and significant dose increase assessment.

None of the systems produced an alert for all the scenarios. System S4 produced the most alerts (for four of the 12 scenarios), with system S1 providing an alert in only one of the scenarios. None of the systems identified the potential allergy to Fluarix, and only S2 and S6 provided an alert to the penicillin sensitivity. Further investigation of the systems showed that in S4 and S5, drug allergy must be recorded per product for allergy checking to take place. With respect to checking for contraindications as a result of age, gender or co-morbidity, a wide range of system responses were observed. System S4 successfully alerted for all of the scenarios presented, S1 did not alert for any of the scenarios and the other systems alerted in less than half of the scenarios. Systems S1, S2 and S5 informed about nonsuitability of aspirin use (C1) in a child of 14 years of age by recording the information on the prescription label or in the message area irrespective of the age of the patient. System S3 did both. It was not possible to record in S6 that a patient was pregnant (C4).

None of the systems identified the overdose of diclofenac in D1. Five of the six systems provided a warning about the use of methotrexate (D2); however, the alert was provided irrespective of the frequency regimen of methotrexate (weekly or daily). None of the ePMR systems appeared to check the dosing frequency entered. The alerts displayed in four of the ePMR systems were based on the National Patient Safety Agency directive regarding weekly dosing of oral methotrexate [26]. In S4,

Table 4

| Test | Dispensing scenario tested | S1 | S2 | S3 | S4 | S5 | S6 |
|------|---------------------------|----|----|----|----|----|----|
| A1   | Sildenafil prescribed to a patient who is also receiving a nitrate | Yes | Yes | Yes | Yes | Yes | Yes |
| A2   | Ciprofloxacin prescribed to a patient who is taking ciclosporin | Yes | Yes | Yes | Yes | Yes | Yes |
| A3   | Clarithromycin prescribed to a patient who is taking digoxin | NO | NO | Yes | Yes | Yes | Yes |
| A4   | Erythromycin prescribed to a patient who is taking simvastatin, with no evidence that the patient has been advised to stop the simvastatin whilst taking the antibiotic | Yes | Yes | Yes | Yes | Yes | Yes |
| A5   | Ibuprofen prescribed to a patient who is taking lithium carbonate | Yes | Yes | Yes | Yes | Yes | Yes |
| A6   | Verapamil prescribed to a patient who is taking atenolol | Yes | Yes | Yes | Yes | Yes | Yes |
| A7   | Naproxen prescribed to a patient who is taking warfarin | Yes | Yes | Yes | Yes | Yes | Yes |
| A8   | Tagamet prescribed to a patient who is prescribed warfarin | Yes | Yes | Yes | Yes | Yes | Yes |
| A9   | Fluvastatin prescribed to a patient who is taking warfarin | Yes | Yes | Yes | Yes | Yes | Yes |
| A10  | Microgynon prescribed to a patient who is on carbamazepine | Yes | Yes | Yes | Yes | Yes | Yes |
| A11  | St John’s Wort prescribed to a patient who is taking fluoxetine | Yes | Yes | Yes | Yes | Yes | NO |
| A12  | Tramacet prescribed to a patient who is already taking paracetamol | Yes | NO | NO | Yes | Yes | Yes |
the weekly regimen was advised in the counselling section of the ePMR software; however, this was contrary to the specific alert layout recommendations of the National Patient Safety Agency. No alert was provided by S3.

Scenario E1 was similar to C5; \(\beta\)-adrenoceptor blocking drugs (in this case, timolol eye drops) should not be used in asthmatic patients (even when administered as eye drops). Unlike C5, where five of the systems correctly alerted the user, for E1 four of the systems failed to warn the dispenser about the potential for harm. Scenarios F1 and F2 were concerned with instances where patients should either be started on a low dose of the medication or should have doses changed gradually. None of the six systems tested provided any warning when presented with these scenarios.

Table 6 shows the results when systems were tested to assess whether unnecessary alerts were provided. Many statins interact with warfarin; however, pravastatin has been shown not to interact. In G1, four of the systems correctly showed no alert, but systems S3 and S5 incorrectly produced alerts. The scenario G2, involving the combined oral contraceptive Microgynon and the antibiotic amoxicillin, was included to assess whether new guidance had been implemented to no longer warn against concomitant non-enzyme-inducing antibiotic use with combined oral contraceptives [27]. Three ePMR systems presented an alert contrary to the revised guidance. Scenario G3 looked at the co-prescribing of two antihypertensive drugs, a very common, and usually appropriate, practice in patients with high blood pressure. Three of the

Table 5
Responses by electronic patient medication record systems in relation to drug allergies, contraindications, inappropriate doses, drug-route suitability, high-dose initiation of medicines and significant dose increase (alert generated = Yes; no alert generated = NO)

| Test | Dispensing scenario tested | Electronic patient medication record system |
|------|---------------------------|---------------------------------------------|
|      |                           | S1  | S2  | S3  | S4  | S5  | S6  |
| B. Drug allergy |                           |     |     |     |     |     |     |
| B1   | Fluarix vaccine prescribed to a patient with egg allergy | NO  | NO  | NO  | NO  | NO  | NO  |
| B2   | Phenoxymethylpenicillin prescribed to a patient with penicillin allergy | NO  | Yes | NO  | NO  | NO  | Yes |
| C. Contraindications (including age, gender and condition) |                           |     |     |     |     |     |     |
| C1   | Aspirin prescribed to a child of 14 years | NO  | NO  | Yes | Yes | NO  | NO  |
| C2   | Acrivastine prescribed to an elderly patient of 70 years | NO  | NO  | NO  | Yes | NO  | NO  |
| C3   | Finasteride prescribed to a female patient | NO  | NO  | NO  | Yes | NO  | NO  |
| C4   | Methotrexate prescribed in pregnancy | NO  | NO  | NO  | Yes | Yes | NO  |
| C5   | Propranolol prescribed to a patient with asthma who is on salbutamol | NO  | Yes | Yes | Yes | Yes | Yes |
| D. Dose check |                           |     |     |     |     |     |     |
| D1   | Diclofenac tablets prescribed above the maximum daily dose recommended by the British National Formulary | NO  | NO  | NO  | NO  | NO  | NO  |
| D2   | Methotrexate prescribed on a daily basis | Yes | Yes | NO  | Yes | Yes | Yes |
| E. Drug-route check |                           |     |     |     |     |     |     |
| E1   | Timolol eye drops prescribed to a patient with salbutamol already in the patient medical record | NO  | NO  | Yes | NO  | Yes | NO  |
| F. High-dose initiation of medicines and significant dose increase |                           |     |     |     |     |     |     |
| F1   | MST Continus 100 mg tablets prescribed to a patient who had 10 mg tablets recorded in the electronic patient medication record system | NO  | NO  | NO  | NO  | NO  | NO  |
| F2   | Morphine sulfate concentrated oral solution prescribed to an opiate-naive patient | NO  | NO  | NO  | NO  | NO  | NO  |

Table 6
Responses by electronic patient medication record systems in clinical scenarios where an alert would not be expected (alert generated = Yes; no alert generated = NO)

| Test | Dispensing scenario tested | Electronic patient medication record system |
|------|---------------------------|---------------------------------------------|
|      |                           | S1  | S2  | S3  | S4  | S5  | S6  |
| G1   | Pravastatin prescribed to a patient who is already taking warfarin to investigate whether electronic patient medication record alerts are attached to individual drugs or whether they are applied at the class level | NO  | NO  | Yes | NO  | Yes | NO  |
| G2   | Amoxicillin prescribed to a patient who is on Microgynon to see whether systems were being updated in line with more recently updated guidance | Yes | NO  | Yes | NO  | NO  | Yes |
| G3   | Atenolol prescribed to a patient who is already taking amlodipine | NO  | NO  | Yes | NO  | Yes | Yes |
| G4*  | Atenolol 75 mg (25 mg + 50 mg), once daily (28 day treatment) | NO  | NO  | NO  | Yes | NO  | NO  |

*Drug-doubling.
systems produced alerts about the use of two similar medicines, whereas three did not. The prescribing of two strengths of the same medicine to achieve a dose not available as a single tablet was tested in G4. Five of the systems appropriately produced no alert.

**Discussion**

The results suggest that current ePMR systems have some deficiencies with respect to highlighting clinical hazards such as drug–drug interactions, co-prescriptions, allergies, contraindications and inappropriate dosing. Although some progress has been made in the development of ePMR systems over the years, there is still a long way to go in bringing the systems up to the level of performance that is now required in clinical practice.

The tests described in Table 1 assessed the performance of ePMR systems with respect to checking drug–drug interactions and hazardous co-prescriptions. All of the medicines a patient receives from a pharmacy are recorded in the ePMR system, so the information is generally readily available to perform these safety checks. However, this is only the case when patients use the same pharmacy. Nevertheless, there would appear to be some cases where known drug–drug interactions are not warned against. If pharmacists rely on the ePMR system to identify these hazardous events, then this is a concern for patient safety. This study was not designed to identify the reasoning behind these events being missed, and further work would be needed to understand why this was the case.

Pharmacists are considered to be experts in medicines and, as well as being aware of specific drug interactions, they are also required to ensure that medicines are used safely based on other key parameters, such as allergies, co-morbidities and issues associated with the age and gender of the patient. The ePMR systems had highly variable performance when checking for issues other than drug–drug interactions. In many cases, few or none of the systems identified the potentially hazardous prescribing. Often, the pharmacist has available only the information presented on the prescription and in the ePMR system along with the information provided by the patient.

In the tests relating to information that could have been provided either from the prescription or from the patient medication record, some of the systems tested were unable to record the required information, such as allergy status, thus preventing appropriate checks being made by the ePMR system. In one instance, allergies could be recorded but these are required to be identified against each medicine; for example, a patient with a penicillin allergy would require an allergy marker being placed against each type of penicillin-based medicine (of which at least six are routinely used in community practice in England). Where allergies could be recorded, none of the systems identified the potential issues with the Fluarix vaccine.

The responses to items prescribed inappropriately to patients based on their age were commonly absent, with only one system correctly identifying both hazardous events. All computer-generated prescriptions now include both the age and date of birth, which can also be verified easily by the patient at the point of dispensing. With this availability, it is surprising that the facility for the ePMR system to verify appropriateness based on age is not generally present.

Our tests showed that the alert for oral methotrexate appeared irrespective of the frequency entered on the label, potentially allowing hazardous daily dosing to be overlooked because this warning appears whether the frequency is correct or not. There was no alert in S3, perhaps due to oversight, lack of awareness of the existence of the National Patient Safety Agency recommendation, or other reasons best known to the pharmacy software vendor company.

In relation to prescribing of morphine, none of the systems alerted to the hazardous practice of initial prescribing of a high dose of medicines to patients or making sudden increases in dose. Given the potential for opioids, such as morphine sulfate, to cause harm to patients [4], high initiation dose and sudden dose increase should alert the user of the system to enable appropriate collaborative management of this potential clinical hazard to take place between the pharmacist and the prescriber and, where relevant, in conjunction with the patient.

It has been reported that alert fatigue can occur when excessive alerts are presented, potentially resulting in important alerts being ignored by the end user [28, 29]. In the tests to check the potential for overalerting, two of the six systems in test G1 triggered unnecessary alerts, suggesting that some systems generate alerts at the drug class level rather than the individual drug level, which may lead to an overpresentation of warnings. Three of the six systems in test G2 provided unnecessary warnings about the use of Microgynon with amoxicillin. This suggests that some systems are not updated in a timely fashion when new guidance becomes available.

**Implications for policy and practice**

*Policy* The results of this study have shown that all of the ePMR systems have inadequacies and do not always produce the same alerts. Given that the ePMR system is intended to be a core element of the service provision in pharmacy, it would seem appropriate for the information to be consistent across systems. At present there is no core specification for the types and content of safety features in ePMR systems in the UK, and there is an urgent need to produce one.
Practice With no core specification and standard system response, it falls to the clinical knowledge of the pharmacist to ensure that all of the items they dispense are clinically appropriate and safe. Many pharmacists work in one pharmacy, but there are some who work in different pharmacies providing cover for days off and holidays. As these systems provide different responses to clinical situations, the pharmacist needs to be fully aware of how the ePMR system they are using will respond, if at all, in a given situation. This work highlights the need for pharmacists not to be over-reliant on ePMR systems.

Strengths and limitations

Strengths One of the strengths of this study is that we tested six of the seven EPS R2 approved ePMR systems available in practice in August 2012, representing almost complete coverage of systems used in community pharmacies in England. This study provides a picture of the ability of ePMR systems and their safety features, in their current state of maturity, to pick up potential clinical hazards and medication errors during pharmacy order entry. It is the first assessment of its type to look at the safety aspects of ePMR systems approved for EPS R2, in the community pharmacy setting in England.

Limitations This study was an assessment of the ability of the systems to inform users about potentially hazardous situations during order entry. It provides information about the current state of maturity of the systems. The assessment was not conducted as a specific test of the sensitivity or specificity of the systems, because the underlying algorithms were not reviewed. It also did not look at how pharmacy professionals react to safety alerts or how they perceive them in practice. Further research would be needed to address these issues.

It is noteworthy that some of the scenarios used in the assessment may, on occasion, be violated for a specific patient; for example, when treatment is started by a specialist consultant in secondary care for continuation in primary care. It was not the intention of this study to allow for these situations, thereby focusing on more routine prescribing in general practice.

Conclusions

The performance of the ePMR systems tested was variable and suboptimal. The findings suggest the need for minimum specifications and standards for ePMR systems to ensure consistency of performance.

Competing Interests

All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

The authors would like to thank all the pharmacies that agreed to participate in the study, and the vendor company that supplied software S6 included in this study.

REFERENCES

1 Mangino PD. Role of the pharmacist in reducing medication errors. J Surg Oncol 2004; 88: 189–94.
2 Pray WS. Help your patients avoid drug interactions. US Pharm 1989; 14: 19–21.
3 Hogan H, Healey F, Neale G, Thomson R, Vincent C, Black N. Preventable deaths due to problems in care in English acute hospitals: a retrospective case record review study. BMJ Qual Saf 2012; 21: 737–45.
4 Cousins DH, Gerrett D, Warner B. A review of medication incidents reported to the National Reporting and Learning System in England and Wales over six years (2005–2010). Br J Clin Pharmacol 2011; 74: 597–604.
5 Averty T, Barber N, Ghaleb M, Dean Franklin B, Armstrong S, Crowe S, Dhillon S, Freyer A, Howard R, Pezzolesi C, Serumaga B, Swanwick G, Talabi O. Investigating the prevalence and causes of prescribing errors in general practice: the PRActiCe Study (PRevalence And Causes of prescribing errors in general practiCe) A report for the GMC. 2012 May.
6 World Health Organisation. WHO – Patient Safety. Available at http://www.who.int/topics/patient_safety/en/ (last accessed 20 November 2013).
7 Rogers PJ, Fletcher G, Rees JE. Reasons for community pharmacists establishing patient medication records. Int J Pharm Pract 1993; 2: 44–8.
8 Rogers PJ, Fletcher G, Rees JE. Clinical interventions by community pharmacists using patient medication records. Int J Pharm Pract 1994; 3: 6–13.
9 Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manage Care Pharm 2006; 12: 383–89.
10 Cremades J, Gonzalez M, Arrebolia I. Relationship between drug interactions and drug-related negative clinical outcomes. Pharm Pract 2009; 7: 34–9.
11 Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 200–4.
12 Saverno KR, Hines LE, Warholak TL, Grizzle AJ, Babits L, Clark C, Taylor AM, Malone DC. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc 2011; 18: 32–7.
13 Heikkila T, Lekander T, Raunio H. Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies. Eur J Clin Pharmacol 2006; 62: 661–65.

14 Jankel CA, Martin BC. Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm 1992; 49: 1430–35.

15 Raebel MA, Carroll NM, Kelleher JA, Chester EA, Berga S, Magid DJ. Randomized trial to improve prescribing safety during pregnancy. J Am Med Inform Assoc 2007; 14: 440–50.

16 Ojeleye O, Avery A, Gupta V, Boyd M. The evidence for the effectiveness of safety alerts in electronic patient medication record systems at the point of pharmacy order entry: a systematic review. BMC Med Inform Decis Mak 2013; 13: 69.

17 Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, Strom BL. Role of computerized physician order entry systems in facilitating medication errors. JAMA 2005; 293: 1197–203.

18 Reason J. Human errors: model and management. BMJ 2000; 320: 768–70.

19 Buurma H, De Smet PA, Egberts AC. Clinical risk management in Dutch community pharmacies – The case of drug-drug interactions. Drug Saf 2006; 29: 723–32.

20 Hatton RC, Rosenberg AF, Morris CT, McKelvey RP, Lewis JR. Evaluation of contraindicated drug-drug interaction alerts in a hospital setting. Ann Pharmacother 2011; 45: 297–308.

21 Health and Social Care Information Centre. Prescriptions Dispensed in the Community, Statistics for England – 2002-2012 [NS]. 2013 Available at http://www.hscic.gov.uk/catalogue/PUB11291 (last accessed 1 August 2013).

22 Kilbridge PM, Alexander L, Ahmad A. Implementation of a system for computerized adverse drug event surveillance and intervention at an Academic Medical Center. J Clin Outcomes Manag 2006; 13: 94–100.

23 Pharmaceutical Services Negotiating Committee. Electronic Prescription Service (EPS). 2014 Available from: http://psnc.org.uk/dispensing-supply/eps/ (last accessed 6 January 2014).

24 British Medical Association, Royal Pharmaceutical Society. British National Formulary (BNF 63). London: BMJ Group and Pharmaceutical Press, 2012.

25 Fernando B, Savelyich BSP, Avery AJ, Sheikh A, Bainbridge M, Horsfield P, Teasdale S. Prescribing safety features of general practice computer systems: evaluation using simulated test cases. BMJ 2004; 328: 1171–72.

26 National Patient Safety Agency. Oral methotrexate tablets – IT requirement specification. 2006 Available from: http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd?AssetID=60036&type=full&servicetype=Attachment (last accessed 20 November 2013).

27 Faculty of Sexual and Reproductive Health Care Clinical Effectiveness Unit. Drug Interactions with Hormonal Contraception. 2011 Available from: http://www.fsrh.org/pdfs/CEuguidancedruginteractionshormonal.pdf (last accessed 4 November 2013).

28 Kesselheim AS, Cresswell K, Phansalkar S, Bates DW, Sheikh A. Clinical decision support systems could be modified to reduce ‘alert fatigue’ while still minimizing the risk of litigation. Health Aff 2011; 30: 2310–17.

29 Horn JR. Designing an effective screening program. ASHP Midyear Clinical Meeting 2006; 41: PI-28.